NEW YORK, Feb. 17, 2024 Rosen Law Firm, a prominent global investor rights law firm, is encouraging investors who purchased securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021, and November 29, 2023, both dates inclusive (the Class Period), to take necessary steps and secure legal counsel before the March 19, 2024 lead plaintiff deadline.
The securities class action lawsuit filed against BioVie Inc. raises serious concerns and allegations regarding potential violations of federal securities laws. Investors are advised to evaluate their eligibility for the role of lead plaintiff, which would allow them to actively participate in the litigation process and potentially recover losses incurred during the Class Period.
The lawsuit alleges that BioVie Inc. made false and/or misleading statements and failed to disclose crucial information to investors about the company’s business, operations, and financial prospects during the Class Period. Specifically, the lawsuit claims that BioVie Inc. made misleading statements regarding the success and effectiveness of its lead drug candidate, NE3107, which is intended for the treatment of refractory ascites due to liver cirrhosis.
Investors who suffered financial damages as a result of purchasing BioVie Inc. securities during the Class Period may be eligible to take legal action to recover losses. By securing legal counsel, investors can ensure their rights are protected and their potential claims are appropriately evaluated, potentially leading to a favorable outcome.
Acting promptly is crucial, as the March 19, 2024 lead plaintiff deadline is rapidly approaching. By seeking legal advice, investors can assess the strength of their claims against BioVie Inc. and determine the best course of action moving forward.
Rosen Law Firm has a proven track record of advocating for the rights of investors and specializes in complex securities litigation. With their extensive experience, they can provide investors with professional guidance and representation, ensuring their best interests are safeguarded throughout the legal process.
If you believe you have incurred losses as a result of purchasing BioVie Inc. securities during the Class Period, it is important to act swiftly. Taking the necessary steps to secure legal counsel can help protect your rights and maximize the potential for recovery.
To join the class action, potential lead plaintiffs are encouraged to visit the firm’s website at www.rosenlegal.com/cases-register-2209.html or contact Phillip Kim of Rosen Law Firm toll-free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com for more information on the lawsuit and the lead plaintiff process.
Comments